The molecular mechanisms causing liver fibrosis, the tissue scarring associated with long-term liver disease, involve an enzyme called Parkin, suggesting that drugs enhancing Parkin activity might delay, reduce or prevent fibrosis. Here, PRKN is linked to liver disorder.